Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 27-34, May 2009

Alternative Indications for Bisphosphonate Therapy

  • Regina Landesberg, DMD, PhD

      Affiliations

    • Associate Professor, Division of Oral and Maxillofacial Surgery, University of Connecticut Health Center, School of Dental Medicine, Farmington, CT. New York Presbyterian Hospital, New York, NY
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Landesberg: Division of Oral and Maxillofacial Surgery, University of Connecticut Health Center, 263 Farmington Ave, L-7056, Farmington, CT 06032
    • ,
  • Sidney Eisig, DDS

      Affiliations

    • George Gutmann Professor of Clinical Craniofacial Surgery and Chairman, Division of Oral Surgery, Columbia University College of Dental Medicine, New York, NY
    • ,
  • Ilene Fennoy, MD

      Affiliations

    • Clinical Professor of Pediatrics–Endocrinology, Medical Director, Comprehensive Adolescent Bariatric Surgery Program, Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY
    • ,
  • Ethel Siris, MD

      Affiliations

    • Madeline C. Stabile Professor of Clinical Medicine, Director, Stabile Osteoporosis Center, Columbia University Medical Center, New York, NY

Bisphosphonates are currently used in the treatment of osteoporosis (postmenopausal and steroid-induced), hypercalcemia of malignancy, Paget's disease of bone, multiple myeloma, and skeletally related events associated with metastatic bone disease in breast, prostate, lung, and other cancers. There are, however, numerous other conditions where a decrease in bone remodeling by bisphosphonates might aid in disease management. The focus of this review will be to discuss a select group of conditions for which bisphosphonate therapy may be efficacious. In this review we present several cases where bisphosphonates have been used as a primary or adjunctive treatment for giant cell lesions of the jaws. Use of bisphosphonate therapy for giant cell tumors of the appendicular skeleton, pediatric osteogenesis imperfecta, fibrous dysplasia, Gaucher's disease, and osteomyelitis will be discussed. Finally, we will review previous in vivo studies on the use of bisphosphonates to augment integration and to treat osteolysis surrounding failing orthopedic implants.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This article discusses off-label usage for all of the drugs that are listed. Dr Landesberg has received honoraria from Novartis Pharmaceutical Corporation. Dr Fennoy states no financial arrangements or affiliations with a corporate organization or a manufacturer of products discussed in this article. Dr Siris has received honoraria and paid consulting fees from Novartis, Procter and Gamble, and Sanofi-Aventis.

PII: S0278-2391(08)01834-X

doi:10.1016/j.joms.2008.12.006

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 27-34, May 2009

Article Tools

* Image Usage & Resolution